Amrutanjan Health Care Analysis

dividend

Pros

• Dividends per share have increased over the past 10 years.
• Dividends paid are well covered by earnings (4x coverage).
• Dividends per share have been stable in the past 10 years.

Cons

• Amrutanjan Health Care's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
• Amrutanjan Health Care's dividend is below the markets top 25% of dividend payers in India (3.08%).

health

Pros

• Amrutanjan Health Care is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
• Amrutanjan Health Care is profitable, therefore cash runway is not a concern.
• Amrutanjan Health Care is profitable, therefore cash runway is not a concern.
• Amrutanjan Health Care has no debt, it does not need to be covered by operating cash flow.
• Amrutanjan Health Care has no debt, it does not need to be covered by short term assets.
• Amrutanjan Health Care's cash and other short term assets cover its long term commitments.
• Amrutanjan Health Care has no debt compared to 5 years ago when it was 4.1%.
• Amrutanjan Health Care has no debt, therefore coverage of interest payments is not a concern.
• Amrutanjan Health Care has no debt.

Cons

• High level of physical assets or inventory.

management

Pros

• The tenure for the Amrutanjan Health Care board of directors is about average.
• Sivalenka's remuneration is lower than average for companies of similar size in India.
• Sivalenka's compensation has been consistent with company performance over the past year, both up more than 20%.

Cons

misc

Pros

Cons

• Amrutanjan Health Care is not covered by any analysts.
• Amrutanjan Health Care has significant price volatility in the past 3 months.

past

Pros

• Amrutanjan Health Care's 1-year earnings growth exceeds its 5-year average (99.2% vs 10.6%)
• Amrutanjan Health Care's year on year earnings growth rate has been positive over the past 5 years.
• Amrutanjan Health Care used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
• Amrutanjan Health Care has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
• Amrutanjan Health Care has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
• Amrutanjan Health Care's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (99.2% vs 22.7%).

Cons

value

Pros

• 590006 outperformed the Market in India which returned -14.5% over the past year.

Cons

• Amrutanjan Health Care's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
• Amrutanjan Health Care's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
• Amrutanjan Health Care is overvalued based on assets compared to the IN Pharmaceuticals industry average.
• Amrutanjan Health Care is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
• Amrutanjan Health Care is overvalued based on earnings compared to the India market.
• 590006 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
• BSE:590006 is up 5.8% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
• BSE:590006 is up 5.8% underperforming the market in India which returned 8% over the past month.